Product Information
BUMETANIDE 0.5 MG TABLET is a generic product labeled by Taro Pharmaceuticals U.S.A. Inc., priced at $0.1288 per EA under NDC 51672422301. Its NADAC has been published 140 times since Jan 31, 2024.
FDA first approved this application on Jul 24, 2023. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
.5 mg/1
Manufacturer
Taro Pharmaceuticals U.S.A. Inc.NDC
51672422301
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
BUMETANIDEApproval Type
Generic (ANDA)
FDA Application
ANDA213458FDA Approved
7/24/2023
TE Code
AB
On Market Since
7/24/2023
Pharmacological Classes
Price Statistics
The NADAC for BUMETANIDE 0.5 MG TABLET has been published 140 times since Jan 31, 2024, and over the history we have for it it has declined 33.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1288 per EA |
|---|---|
| All-time high | $0.2136 (Mar 13, 2024) |
| All-time low | $0.1213 (May 22, 2024) |
| 52-week high | $0.1428 |
| 52-week low | $0.1250 |
| Median price | $0.1425 |
| Average price | $0.1482 |
| Largest weekly change | +29.3% (Jun 19, 2024) |
| Weeks tracked | 140 |
| Tracking since | Jan 31, 2024 |
Generic Alternatives
The matcher finds 7 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Taro Pharmaceuticals U.S.A. Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Bumetanide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Loop Diuretic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BUMETANIDE 0.5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for BUMETANIDE 0.5 MG TABLET, manufactured by Taro Pharmaceuticals U.S.A. Inc., is $0.1288 per EA (NDC 51672422301), effective Sep 30, 2026.
How has the price of BUMETANIDE 0.5 MG TABLET changed over time?
Over the history we have for it, the NADAC for BUMETANIDE 0.5 MG TABLET has declined 33.9%. It has been tracked across 140 weekly CMS publications since Jan 31, 2024.
What are the highest and lowest recorded NADAC prices for BUMETANIDE 0.5 MG TABLET?
Since Jan 31, 2024, the NADAC for BUMETANIDE 0.5 MG TABLET has ranged from a low of $0.1213 (May 22, 2024) to a high of $0.2136 (Mar 13, 2024), with a median of $0.1425 per EA.
Are there cheaper alternatives to BUMETANIDE 0.5 MG TABLET?
7 manufacturers publish a NADAC-priced product with the same active ingredient and strength as BUMETANIDE 0.5 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures BUMETANIDE 0.5 MG TABLET?
BUMETANIDE 0.5 MG TABLET (NDC 51672422301) is labeled by Taro Pharmaceuticals U.S.A. Inc., and CMS classifies it as a generic product.